•  
  •  
 

Subject Area

Cardiology and Vascular Medicine

Article Type

Original Study

Abstract

Objective The objective of this study was to evaluate the efficacy of inhaled salbutamol for the treatment of transient tachypnea of the newborn (TTN). Background The most commonly reported cause of neonatal respiratory distress is TTN, with estimated incidence of 0.5–2.8% of all newborn. Patient and methods This is a randomized controlled trial study considering patient with even registration number as cases. Inhaled salbutamol or normal saline solution was administered to 60 infants diagnosed as having TTN. The response was evaluated by determining respiratory rate, heart rate, TTN clinical score, and level of respiratory support, before and at 30 min and 1 and 4 h after drugs therapy. The standard dose of salbutamol was 0.15 mg/kg added to 2 ml normal saline. The second group received dose of 2 ml nebulized (0.9%) normal saline only. Results The studied neonates were between 36 and 39 weeks of gestation. There were 30 (50%) males and 30 (50%) females. Comparing the two groups after 4 h of inhaled therapy, highly significant lower respiratory rate, oxygen, TTN score, respiratory support, and duration of hospitalization were detected in salbutamol group rather than saline group. Regarding arterial blood gas findings after 4 h of inhaled therapy, pH and partial pressure of arterial oxygen were significantly higher in salbutamol group than saline group. No significant difference was detected between the two groups regarding heart rate and serum potassium. Conclusion A single dose of inhaled salbutamol resulted in better clinical aspect and better laboratory outcome measures in cases of TTN.

Download

Share

COinS